Daniel C. Md Adelman Sells 26,784 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Daniel C. Md Adelman sold 26,784 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $40.00, for a total value of $1,071,360.00. Following the completion of the transaction, the insider now directly owns 26,784 shares in the company, valued at approximately $1,071,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at $37.83 on Thursday. Aimmune Therapeutics, Inc. has a twelve month low of $15.97 and a twelve month high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. sell-side analysts anticipate that Aimmune Therapeutics, Inc. will post -2.51 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 499 shares during the period. Legal & General Group Plc grew its holdings in Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares during the period. American International Group Inc. grew its holdings in Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after acquiring an additional 1,764 shares during the period. Wells Fargo & Company MN grew its holdings in Aimmune Therapeutics by 3.4% during the third quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock worth $1,519,000 after acquiring an additional 2,025 shares during the period. Finally, Daiwa SB Investments Ltd. grew its holdings in Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 2,245 shares during the period. 73.34% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on AIMT. Robert W. Baird began coverage on Aimmune Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 target price on the stock. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Saturday, October 21st. Credit Suisse Group boosted their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $55.43.

WARNING: “Daniel C. Md Adelman Sells 26,784 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://stocknewstimes.com/2018/01/18/daniel-c-md-adelman-sells-26784-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply